Portola's Heart Bypass Drug Gets Closed Advisory Committee Session
This article was originally published in The Pink Sheet Daily
FDA's Cardiovascular and Renal Drugs Advisory Committee will discuss Portola Pharmaceuticals' thromboxane receptor antagonist PRT061103, intended to prevent cardiovascular problems in patients who have developed intolerance to aspirin.
You may also be interested in...
Endo's Advisory Committee Cancelled
A claim for tamper-resistance rather than broad abuse-deterrence appears to be the immediate path forward for companies seeking to differentiate a new opioid product by its ability to impede recreational use.
Portola's anti-thrombotic vision: Execs discuss possibilities for two partnered, Phase III ready drugs - elinogrel and betrixaban.